SunTrust analyst Sandy Draper raised his price target on Teladoc to $75 and kept his Buy rating, saying the review of his financial model and conversations with the company management suggest that its FY19 guidance has been set too conservatively. The analyst believes that Teladoc’s two key metrics – paying members and utilization – will exceed his prior expectations and also offers a more positive outlook on the “wide-scale telehealth adoption” given the company’s “strong sales pipeline and an increasingly more favorable legislative environment.”
https://thefly.com/landingPageNews.php?id=2873539
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.